Compare Bandwidth Inc (BAND) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bandwidth Inc vs Merck & Co., Inc. — how do they compare? Bandwidth Inc trades at $71.3 (market cap $2.36B), while Merck & Co., Inc. trades at $123.28 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 126.4× Bandwidth Inc's market cap, and Merck & Co., Inc. pays a 2.82% dividend while Bandwidth Inc pays none. Which is the better fit depends on your goals.
| BAND | MRK | |
|---|---|---|
Market Cap | $2.36B | $298.31B |
Sector | Technology | Health |
52-Week High | $78.44 | $129.52 |
52-Week Low | $12.82 | $77.60 |
Enterprise Value | $2.74B | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bandwidth (BAND) trades at $73.81, down 2.21% today, with strong technical momentum indicated by bullish moving averages. The company reported Q1 2026 EPS of $0.38, beating expectations of $0.32, while revenue reached $753.82 million in 2025. Analyst sentiment is positive with 12 buy ratings and a consensus price target of $71.67. Recent news highlights AI-driven growth in cloud communications and a $275 million convertible notes offering to fuel expansion.
The outlook for BAND is cautiously optimistic, driven by AI infrastructure demand and cloud communications growth. Key risks include negative profit margins and high valuation multiples. Investment opportunity lies in execution of AI initiatives, but investors should monitor earnings sustainability and competitive pressures in the technology sector.
Merck (MRK) trades at $120.8, down 2.6% on the day, with a bullish technical signal and strong support near $120. Recent earnings have consistently beaten expectations, including Q1 2026's smaller-than-expected loss. The company is acquiring Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives. Revenue reached $65.01B in 2025 with a net income margin of 28.07%, though 2026 projections show a decline to 13.58%.
The outlook remains positive with a consensus price target of $137.30, implying 13.7% upside. Key opportunities include pipeline expansion via M&A and robust profitability, but risks involve rising debt, patent expirations, and competitive pressures. Institutional buying activity supports bullish sentiment, though earnings volatility and macroeconomic factors warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bandwidth Inc
Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
